A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users

NCT02144415 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers
Drug Users

Interventions

DRUG: EB-1020 400 mg
DRUG: EB-1020 800 mg
DRUG: lisdexamfetamine 150 mg
DRUG: d-amphetamine 40 mg
DRUG: Placebo

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.